Aranosa (Aranose)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Similar drugsTo uncover
Dosage form: & nbsplyophilizate for solution for injection
Composition:

1 bottle contains:

Active substance: aranose 500 mg.

Excipients: polyvinylpyrrolidone low molecular weight M.M. 12600, the acid is sorbic.

Description:Dry porous mass of white with a yellowish tinge.
Pharmacotherapeutic group:An antitumour agent, an alkylating compound
Pharmacodynamics:

Aranosa has an antitumor effect (inhibits the synthesis of DNA in tumor cells). The strength and spectrum of the antitumor effect is close to nitrosourea. Has the advantage over analogues in a greater breadth of therapeutic doses, in the possibility of application in outpatient settings.

Indications:

Melanoma of the skin.

Contraindications:

The general severe condition of the patient, leukopenia below 3000 and thrombocytopenia below 120000 in 1 mm3 blood, peptic ulcer of the stomach and duodenum in the stage of exacerbation; severe cardiovascular, neurological diseases, violations of liver and kidney function, pregnancy and the period of breastfeeding.

Dosing and Administration:

Aranose is injected intravenously in a single dose of 550-800 mg / m2 surface of the patient's body. The drug is prescribed daily or every other day. The course of treatment 3 injections (on average, the total dose is 3.0 - 4.5 g of the drug).

The solution is prepared immediately before injection by dissolving the contents of the vial (500 mg of the drug) in 20 ml of a 5% solution of glucose.

Repeated courses are carried out with an interval of 4 weeks in the absence of any manifestations of toxicity.

Treatment is carried out under the control of the content of leukocytes, platelets, erythrocytes in the blood. It should be borne in mind that signs of bone marrow suppression may appear 1-3 weeks after the end of the course of treatment.

Side effects:

The drug depresses leukopoiesis, thrombocytopoiesis, to a lesser extent - erythropoiesis; disrupts the function of the gastrointestinal tract; has an immunosuppressive effect. Side effects of treatment with aranose are reversible and do not limit the conduct of chemotherapy.

Interaction:

The use of aranose in combination with other antitumor drugs leads to an increase in its effectiveness in the treatment of disseminated skin melanoma and is not accompanied by increased toxicity.

Form release / dosage:

Lyophilizate in bottles of 500 mg.

Packaging:6 bottles per package.
Storage conditions:

List A.

Store in a dry, dark place out of the reach of children, at a temperature not higher than + 10 ° C (refrigerator conditions).

Shelf life:

Shelf life 3 years.

Do not use after the expiry date printed on the package.

Terms of leave from pharmacies:On prescription
Registration number:P N000449 / 02
Date of registration:14.05.2009 / 05.12.2013
The owner of the registration certificate:RNTS named after N.N. Blokhin RAMS RNTS named after N.N. Blokhin RAMS Russia
Manufacturer: & nbsp
Information update date: & nbsp25.02.2016
Illustrated instructions
    Instructions
    Up